1 October 2021 in International Journal of General Medicine
Introduction: COVID-19 is a pandemic with significant mortality and it is important to differentiate severe and non-severe cases. We conducted a study to evaluate hematologic profiles with inflammation markers in COVID-19 patients and to determine the correlation of neutrophil-lymphocyte ratio (NLR) with disease severity. Methods: A cross-sectional study involving hospitalized COVID-19 patients confirmed with a positive SARS-CoV-2 PCR test in Dr. Cipto Mangunkusumo Hospital. Lymphocyte count, NLR, C-reactive protein (CRP) and ferritin were evaluated in severe and non-severe COVID-19 cases at hospital admission. Data was analyzed using Spearman correlation. Results: There were 41 patients aged 20 to 79 years with COVID-19; 33 (80.5%) were non-severe, and 8 (19.5%) were severe cases. There is a statistically significant difference in WBC, relative neutrophils and lymphocytes, NLR, and CRP between non-severe and severe cases. There is a strong correlation between NLR and CRP (r = 0.738; p < 0.001). Our findings show that NLR and absolute lymphocyte count, but not ferritin, play a role in differentiating between non-severe and severe COVID-19 cases. Conclusion: In COVID-19 cases, a strong correlation between NLR and CRP might suggest the use of NLR to differentiate between non-severe and severe cases, especially in a remote healthcare facility.
1 August 2023 in International Journal of General Medicine
Introduction: Metastatic breast cancer was associated with high morbidity and mortality. Insulin resistance was hypothesized to be related to the incidence of advanced breast cancer. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Triglyceride/Glucose Index (TyG Index) are two metrics used to measure the degree of insulin resistance. This study aims to assess the relationship between the incidence of metastatic breast cancer and insulin resistance as reflected by both metrics. Material and Methods: This study is a cross-sectional study involving 150 primary invasive breast cancer patients recruited from two hospitals of different sectors from August 2019 to April 2020. Patients with double cancer and autoimmune disorder were excluded from this study. Data obtained from the patients include age, body mass index (BMI), type 2 diabetes mellitus (T2DM) status and treatment, and low-density lipoprotein (LDL) cholesterol. The electronic medical records (EMR) was consulted to find histopathology examination result, cancer staging, and any missing data. The association between HOMA-IR and TyG with metastatic incidence was analyzed using either the Mann–Whitney test (for non-normally distributed data) or the independent-sample t-test (for normally distributed data). Results: The mean of the TyG index is 8.60, and the median of HOMA-IR is 1.22. We found no significant correlation between both variables and the incidence of metastases. Conclusion: Insulin resistance was not associated with metastatic breast cancer.
31 January 2023 in The Journal of Infection in Developing Countries
Introduction: Covid Convalescent Plasma (CCP) failed to demonstrate its efficacy in severe and life-threatening coronavirus disease 2019 (COVID-19) cases. However, the role of CCP in hospitalized moderate cases is unclear. This study aims to examine the efficacy of administering CCP to hospitalized moderate coronavirus disease 2019 patients. Methodology: An open-label randomized controlled clinical trial design was used from November 2020 – August 2021 at two referral hospitals in Jakarta, Indonesia, and the primary outcome was mortality at 14 days. The secondary outcomes were mortality at 28 days, the time-to-discontinuation of supplemental oxygen, and the time-to-hospital discharge. Results: This study recruited 44 subjects, and the intervention arm consisted of 21 respondents who received CCP. The control arm consisted of 23 subjects who received standard-of-care treatment. All subjects survived during the fourteen-day follow-up period, and the 28-day mortality rate in the intervention group was lower than the control (4.8% vs 13.0%; p = 0.16, HR = 4.39 (95% CI = 0.45-42.71). There was no statistically significant difference in the time-to-discontinuation of supplemental oxygen and time-to-hospital discharge. During the total follow-up period (41 days), the mortality rate in the intervention group was also lower than the control (4.8% vs 17.4%, p = 0.13, HR = 5.47, 95% CI = 0.60–49.55). Conclusions: This study concluded that in hospitalized moderate COVID-19 patients, CCP did not reduce 14-day mortality compared to the control. Mortality during 28 days and total length of stay (41 days) were lower in the CCP group compared to the control, although they did not reach statistical significance.
24 September 2020 in Respirology Case Reports
Primary mediastinal B‐cell lymphoma (PMBCL) is a rare tumour with different characteristics from other type of lymphomas. Clinical manifestations may vary and cause delay in diagnosis and management. We present a 22‐year‐old patient with symptoms of shortness of breath, weight loss, and night sweats. Laboratory studies only showed a markedly high lactate dehydrogenase (LDH) level and thoracic computed tomography (CT)scan revealed a large mediastinal mass. Core biopsy‐guided CT scan was performed and the pathological and immunohistochemistry established a PMBCL diagnosis. We administered Rituximab Dose‐Adjusted Etoposide Prednisolone Vincristine Cyclophosphamide Doxorubicin (R‐DA‐EPOCH) chemotherapy regimen and the patient responded well to treatment. This is an example of rare case of mediastinal lymphoma with challenges to overcome to achieve diagnostic and therapeutic success. Failure to differentiate PMBCL with other systemic diffuse large B‐cell lymphoma (DLBCL) could skew treatment algorithm and prevent optimal response. Administration of proper systemic therapy, especially in young, low‐risk patients could yield excellent outcome.
29 August 2022 in Electronic Journal of General Medicine
Background: Nasopharyngeal carcinoma (NPC) is a leading cause of cancer related death in Asia; and the fourth most common malignancy in Indonesia. Hypothyroidism is one of the most commonly overlooked radiotherapy-induced late side effect due to its gradual occurrence despite its irreversibility. Unfortunately, thyroid evaluation is not widely accessible throughout Indonesia. Therefore, it is quite important to utilize a simple and reliable surrogate tool for hypothyroidism screening. This study aims to evaluate thyroid function and to validate Zulewski’s scoring system as a temporary surrogate marker for hypothyroidism in post-RT NPC patients. Method: This is a cross-sectional study involving NPC patients between November 2015 and March 2016 at Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. The patients had completed radiation therapy (RT) within the preceding six months. They were evaluated for signs and symptoms of hypothyroidism with Zulewski’s clinical scoring system and with serological analysis of thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels. Results: There were 97 patients in this study. 28 (28.9%) subjects experienced hypothyroidism based on the TSH and FT4 levels, with subclinical hypothyroidism (13.4%) as the most common type, followed by overt hypothyroidism (9.3%) and hypothyroxinemia (6.2%). From the subjects with hypothyroidism, 19.6% had Zulewski’s clinical score <5, while 40.5% had scores ≥5. Subjects with <5 Zulewski’s clinical score exhibited signs and symptoms more related to the NPC itself, while those who scored ≥5 showed signs and symptoms more closely related to hypothyroidism. Conclusion: This study shows that hypothyroidism is commonly exhibited in NPC patients after radiotherapy (28.9%). Zulewski’s clinical score of ≥5 indicates signs and symptoms more closely related to hypothyroidism.
23 April 2014 in eJournal Kedokteran Indonesia